This October 2024 image provided by Novartis shows GanLum, a new anti-malaria treatment, at a manufacturing facility in Slovenia. Novartis via AP
NEW YORK—Researchers on Wednesday reported two promising new approaches to counteract malaria’s growing resistance to medication — one involving a new class of drugs.
Switzerland-based Novartis released results of what it called a next-generation treatment. A study of its experimental drug in 12 African countries found it works well against the mosquito-borne parasite that causes malaria and seems to block spread.
